Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia
| Autor: | Shai Levi, Miguel Morales, Yotam Bronstein, Anat Amit Aharon, Erel Joffe, Yair Herishanu, Irit Avivi, Yamit Shorer Arbel, Gabi Shefer, Chava Perry, Paolo Ghia, Tomer Ziv, Lydia Scarfò |
|---|---|
| Přispěvatelé: | Herishanu, Y., Avivi, I., Aharon, A., Shefer, G., Levi, S., Bronstein, Y., Morales, M., Ziv, T., Shorer Arbel, Y., Scarfo, L., Joffe, E., Perry, C., Ghia, P. |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
COVID-19 Vaccines Clinical Trials and Observations Chronic lymphocytic leukemia COVID-19 Vaccine Immunology Biochemistry Gastroenterology Immunoglobulin G chemistry.chemical_compound Internal medicine Medicine Humans RNA Messenger NEOPLASIA/Lymphoid leukemias BNT162 Vaccine Aged biology business.industry Venetoclax SARS-CoV-2 Antibody titer COVID-19 Regular Article Cell Biology Hematology Odds ratio antibody response medicine.disease vaccination Leukemia Lymphocytic Chronic B-Cell Vaccination chemistry Immunoglobulin M biology.protein NEOPLASIA/lymphoid leukemias BNT162b2 Female Antibody business COVID-19 vaccine CLL |
| Zdroj: | Blood |
| Popis: | Patients with chronic lymphocytic leukemia (CLL) have an increased risk for severe COVID-19 disease and mortality. The goal of this study was to determine the efficacy of COVID-19 vaccine in patients with CLL. We evaluated humoral immune responses to the BNT162b2 messenger RNA (mRNA) COVID-19 vaccine in patients with CLL and compared responses with those obtained in age-matched healthy control subjects. Patients received 2 vaccine doses, 21 days apart, and antibody titers were measured by using the Elecsys Anti-SARS-CoV-2 S assay after administration of the second dose. In a total of 167 patients with CLL, the antibody response rate was 39.5%. A comparison between 52 patients with CLL and 52 sex- and aged-matched healthy control subjects revealed a significantly reduced response rate among patients (52% vs 100%, respectively; adjusted odds ratio, 0.010; 95% confidence interval, 0.001-0.162; P < .001). The response rate was highest in patients who obtained clinical remission after treatment (79.2%), followed by 55.2% in treatment-naive patients and 16.0% in patients under treatment at the time of vaccination. In patients treated with either Bruton’s tyrosine kinase inhibitors or venetoclax ± anti-CD20 antibody, response rates were considerably low (16.0% and 13.6%). None of the patients exposed to anti-CD20 antibodies |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|